Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors.
Di Nicolantonio
Federica
F
Translational Oncology Research Centre, Department of Histopathology, Queen Alexandra Hospital, Portsmouth PO6 3LY, UK.
Knight
Louise A
LA
Di Palma
Silvana
S
Sharma
Sanjay
S
Whitehouse
Pauline A
PA
Mercer
Stuart J
SJ
Charlton
Peter A
PA
Norris
David
D
Cree
Ian A
IA
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor / Q000379:methods; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D010619:Phenazines / Q000008:administration & dosage*; D018709:Statistics, Nonparametric; D014407:Tumor Cells, Cultured
C446952:4-methoxybenzo(a)phenazine-11-carboxylic acid (2-(dimethylamino)-1-methylethyl)amide; D010619:Phenazines